News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
106last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
Pharmaceutical Technology4d agoneutral
AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with NxeraGuruFocus.com4d agoneutral
Capital Group Cons. Equity (CGCV) Adds Microsoft and Philip Morris on MondayGuruFocus.com4d agoneutral
State Street Health Care SPDR (XLV) Adds Eli Lilly and J&J on Nov. 2MT Newswires4d agoneutral
AbbVie Enters Global License Deal With Nxera Pharma for Experimental IBD DrugGlobeNewswire4d agoneutral
Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026Pharmaceutical Technology5d agoneutral
AbbVie inks $757m migraine-focused deal with Brise PharmaceuticalsPharma Voice5d agobearish
Lilly’s R&D whirlwind - what the large pharma has taken in and what it’s droppedStockStory6d agoneutral
ABBV Q3 deep dive: Immunology and neuroscience drive growth, pipeline progress continuesGuruFocus.com6d agoneutral
AbbVie Stocks Decline 2.3% With RBC Target Increase Backing Its Immunology Transition